KPTI
insider transactionsKaryopharm Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-4.1K
0 buy · 4.1K sell
Net value · 90d
-$38.8K
$0 in · $38.8K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
7
0 buy · 4.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own +1710%
-
Sell·S
EVP, Chief Development Officer
$3.8K
403 sh · $9.50
Own -0%
-
Sell·S
EVP & Chief Medical Officer
$3.9K
408 sh · $9.50
Own -1%
-
Sell·S
President and CEO
$20.9K
2.2K sh · $9.50
Own -1%
-
Sell·S
EVP, CLO&Secretary
$2.5K
266 sh · $9.50
Own -0%
-
Sell·S
EVP & Chief Commercial Officer
$3.1K
324 sh · $9.50
Own -0%
-
Sell·S
Chief Accounting Officer
$504
53 sh · $9.50
Own -0%
-
Grant·A
EVP, Chief Development Officer
$0
896 sh
Own +1%
-
Grant·A
EVP & Chief Medical Officer
$0
947 sh
Own +2%
-
Grant·A
President and CEO
$0
4.9K sh
Own +2%
-
Grant·A
EVP, CLO&Secretary
$0
700 sh
Own +1%
-
Grant·A
EVP & Chief Commercial Officer
$0
947 sh
Own +1%
-
Grant·A
Chief Accounting Officer
$0
121 sh
Own +1%
-
Sell·S
EVP & Chief Medical Officer
$4.0K
449 sh · $8.94
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Zhen Su | Grant A | 15.5K | $0 |
| May 21, 2026 | Christy J. Oliger | Grant A | 15.5K | $0 |
| May 21, 2026 | Chen Schor | Grant A | 15.5K | $0 |
| May 21, 2026 | Deepika Pakianathan | Grant A | 15.5K | $0 |
| May 21, 2026 | Barry E Greene | Grant A | 15.5K | $0 |
| May 14, 2026 | Stuart Poulton | Sell S | 403 | $3.8K |
| May 14, 2026 | Reshma Rangwala | Sell S | 408 | $3.9K |
| May 14, 2026 | Richard A. Paulson KEY | Sell S | 2.2K | $20.9K |
| May 14, 2026 | Michael Mano | Sell S | 266 | $2.5K |
| May 14, 2026 | Sohanya Roshan Cheng | Sell S | 324 | $3.1K |
| May 14, 2026 | Kristin Abate | Sell S | 53 | $504 |
| May 13, 2026 | Stuart Poulton | Grant A | 896 | $0 |
| May 13, 2026 | Reshma Rangwala | Grant A | 947 | $0 |
| May 13, 2026 | Richard A. Paulson KEY | Grant A | 4.9K | $0 |
| May 13, 2026 | Michael Mano | Grant A | 700 | $0 |
| May 13, 2026 | Sohanya Roshan Cheng | Grant A | 947 | $0 |
| May 13, 2026 | Kristin Abate | Grant A | 121 | $0 |
| Apr 21, 2026 | Reshma Rangwala | Sell S | 449 | $4.0K |
About KPTI insider trading
This page tracks insider transactions for Karyopharm Therapeutics Inc. (KPTI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.